One of the major aims of HIV-1 vaccine research is to stimulate the generation of HIV-1-neutralising antibodies (nAbs), which can effectively hinder infection. However, there is limited knowledge regarding the induction and persistence of these nAbs in the plasma of HIV-1-infected individuals receiving uninterrupted antiretroviral therapy (uART) and who have been virologically suppressed since HIV-1 diagnosis. To assess the occurrence of HIV-1-neutralising antibodies, we carried out a study that involved the examination of plasma IgG-mediated neutralisation against a panel of 12 global HIV-1 pseudoviruses. This study was conducted with a cohort of 185 HIV-1 patients who were undergoing uART and had undetectable HIV-1 viremia at the time of sampling. Our preliminary findings show that 6.5% of total HIV-1 patients exhibited elite neutralising capabilities to neutralise all 12 global HIV-1 panels, while the overall mean neutralisation potency stood at 25%. Notably, individuals with CD4+ T cell counts below 200 cells/μL were significantly more likely to exhibit neutralisation function. In summary, our research underscores the importance of understanding the maintenance of HIV-1 nAbs in individuals under uART. Despite the historical prevalence of HIV-1 subtype C among Nepalese HIV-1 patients, neutralisation patterns exhibit diversity, potentially impacting vaccine development and the identification of elite neutralisers within the population.